DISCOUNT OPTIONSSCHEIN - NOVO NORDISK ADR B | Real-time Boerse Frankfurt Warrants 14:04:00 2024-06-24 EDT | ||
| 0.7 EUR | 0.00% |
|
| Current month | +27.27% | ||
| 1 month | +16.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-24 | 0.7 | 0.00% |
| 24-06-21 | 0.7 | +1.45% |
| 24-06-20 | 0.69 | 0.00% |
| 24-06-19 | 0.69 | +2.99% |
| 24-06-18 | 0.67 | -1.47% |
Real-time Boerse Frankfurt Warrants
Last update June 24, 2024 at 02:04 pm
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD3WSZ |
| ISIN | DE000VD3WSZ6 |
| Date issued | 2024-04-10 |
| Strike | 150 $ |
| Maturity | 2025-03-21 (270 Days) |
| Parity | 10 : 1 |
| Emission price | 0.37 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.74 € |
|---|---|
| Lowest since issue | 0.4 € |
| Spread | 0.01 € |
| Spread % | 1.39% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
988.4
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.48%
- Stock Market
- Certificates
- Certificat
